Skip to content
Pharma Observatory a Scientist.com platform

Gene

STAG2

STAG2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (1), Trial mentions (27), and 6 more evidence types, each linked to its source.

Ensembl ENSG00000101972 UniProt Q8N3U4 Matched to Ensembl and UniProt
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Assay-provider ledger Assay-provider ledger 2 Actionable biomarkers Actionable biomarkers 1 Trial mentions Trial mentions 27 Target-disease associations Target-disease associations 260 Vendor sourcing Vendor sourcing 111 Trial-cited literature Trial-cited literature 98 Protein variant mentions Protein variant mentions 11 Literature-extracted relations Literature-extracted relations 12 Assay-provider ledger Assay-provider ledger 2 Actionable biomarkers Actionable biomarkers 1 Trial mentions Trial mentions 27 Target-disease associations Target-disease associations 260 Vendor sourcing Vendor sourcing 111 Trial-cited literature Trial-cited literature 98 Protein variant mentions Protein variant mentions 11 Literature-extracted relations Literature-extracted relations 12

Rows recorded per section (log scale)

1 more section with rows · 3 sections measured, none recorded

Cancer actionable (CGI)

Curated as clinically actionable in cancer by the Cancer Genome Interpreter.

Get the STAG2 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Evidence over time

Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention STAG2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.

Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.

Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.

The yearly numbers
STAG2 per year, by evidence type, the most recent 10 years, newest first; the chart covers 1990 to 2026. The share is of the trials and papers our biomarker dictionary matched that year, not of the literature at large, and a blank year is one our matched corpus does not cover at all.
Year Trial mentions Share of that year Publication mentions Share of that year
2026 1 of 8,738 0.01% not measured
2025 5 of 8,875 0.06% not measured
2024 4 of 8,597 0.05% not measured
2023 2 of 8,275 0.02% 14 of 11,460 0.12%
2022 3 of 8,285 0.04% 8 of 13,598 0.06%
2021 7 of 8,692 0.08% 8 of 15,045 0.05%
2020 1 of 7,640 0.01% 10 of 14,459 0.07%
2019 1 of 7,300 0.01% 7 of 12,159 0.06%
2018 1 of 6,927 0.01% 11 of 11,854 0.09%
2017 0 of 6,558 0.00% 10 of 11,595 0.09%

Showing 10 of 37 years.

Start your 14-day trial Email me all 37 years as a PDF

Assay-provider ledger (2)

Shown in this order: most recent publication first.

Assay-provider ledger
Company Provider class Validation Papers Most recent publication
QIAGEN Reagent supplier Clinical validation 1 October 01, 2019
THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) Reagent supplier Clinical validation 1 October 01, 2019

Actionable biomarkers (1)

Shown in this order: fixed catalogue order, not ranked.

Actionable biomarkers
Alteration Drug Response Disease Source
STAG2 oncogenic mutation Parp Inhibitors response-associated glioma Cancer Genome Interpreter

Trial mentions (27)

Shown in this order: fixed catalogue order, not by date.

Trial mentions
Trial Source
NCT04659616 Trial eligibility (AACT)
NCT05583175 Trial eligibility (AACT)
NCT06972641 Trial eligibility (AACT)
NCT06297629 Trial eligibility (AACT)
NCT05599672 Trial eligibility (AACT)

Showing 5 of 27 trial mentions.

Start your 14-day trial Email me all 27 trial mentions as a PDF

Target-disease associations (260)

Shown in this order: fixed catalogue order, not ranked.

Target-disease associations
Disease Therapeutic area Source
ACTH-Producing Pituitary Gland Adenoma cancer or benign tumor Cancer Gene Census
Abnormal heart morphology phenotype genomics england
Abnormality of head or neck phenotype genomics england
Adenoid Cystic Breast Carcinoma cancer or benign tumor Cancer Gene Census
Ampulla of Vater Carcinoma cancer or benign tumor Cancer Gene Census

Showing 5 of 260 associations.

Start your 14-day trial Email me the first 50 associations as a PDF

Vendor sourcing (111)

Shown in this order: alphabetical by organization.

Vendor sourcing
Organization Role Tier Evidence Citation
3billion, Inc. (South Korea) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense variants In silico tool predictions suggest damaging effec... View ClinVar record SCV005905039.1
ARUP Laboratories (United States) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission No supporting text recorded; see the citation. View ClinVar record SCV005876511.1
Ambry Genetics (United States) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission The alteration results in an amino acid change:_x000D_ _x000D_ The c.631C>G (p.Q211E) alteration is located in exon 8 (coding exon 6) of the STAG2 gene. This... View ClinVar record SCV001445319.4
Astex Pharmaceuticals Trial collaborator Named in trial inclusion criteriaTrial eligibility criteria : * Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first or second allogeneic HSCT with either peripher... View trial NCT06297629
Astex Pharmaceuticals Trial collaborator Mentioned in trial textTrial free-text mention STAG2 View trial NCT06297629

Showing 5 of 111 sourcing records.

Start your 14-day trial Email me the first 50 sourcing records as a PDF

Trial-cited literature (98)

Shown in this order: newest first, then most cited.

Trial-cited literature
Publication Journal Year Citations
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. American journal of hematology 2026 0
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia 2024 35
Recent advances in targeted therapies in acute myeloid leukemia. Journal of hematology & oncology 2023 207
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 104
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 75

Showing 5 of 98 papers.

Start your 14-day trial Email me the first 50 papers as a PDF

Protein variant mentions (11)

Shown in this order: alphabetical by variant.

Protein variant mentions
Variant Distinct papers Year range Sample papers
p.C535* 1 2015 PMID 25741868
p.I2T 1 2015 PMID 25741868
p.L997X 1 2022 PMID 34893945
p.M13F 1 2013 PMID 24121789
p.Q140* 1 2015 PMID 25741868

Showing 5 of 11 variants.

Start your 14-day trial Email me all 11 variants as a PDF

Literature-extracted relations (12)

Shown in this order: chemicals, then diseases.

Literature-extracted relations
Related entity Kind Source relation label Paper Year
Leukemia, Myeloid, Acute Disease associate Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. 2020
Myelodysplastic Syndromes Disease associate Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. 2020
Sarcoma, Ewing Disease associate Ewing sarcoma. 2018
Leukemia, Myeloid, Acute Disease associate Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. 2015
Leukemia, Myeloid, Acute Disease associate Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. 2014

Showing 5 of 12 relation assertions.

Start your 14-day trial Email me all 12 relation assertions as a PDF

Organizations publishing (205)

Shown in this order: most papers first.

Organizations publishing
Organization Type Papers Years
Memorial Sloan Kettering Cancer Center Hospital 12 2015 to 2023
Dana-Farber Cancer Institute Other 9 2015 to 2023
Government of the United States of America Government 6 2014 to 2023
Harvard Medical School Academic 6 2015 to 2023
The University of Texas System Academic 6 2013 to 2026

Showing 5 of 205 organizations.

Start your 14-day trial Email me the first 50 organizations as a PDF

Where STAG2 appears

  • biological_process
  • cancer or benign tumor
  • endocrine system disease
  • genetic, familial or congenital disease
  • hematologic disease
  • infectious disease
  • measurement
  • nervous system disease
  • phenotype

228 diseases touched.

Not on this page

Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.

Browse all biomarker evidence pages